# Modern drug-development modalities, 2016–2026

**Evidence cutoff:** 6 August 2026  
**Audience:** PhD-level biologist  
**Inclusion rule:** an included therapeutic platform must have at least human Phase II evidence; the core list is more stringent—approval or convincing randomized Phase II/III validation wherever possible. Accelerated approval and single-arm response data are labeled as weaker evidence rather than treated as equivalent to survival benefit.

## Executive view

The most useful unifying idea is **programmable pharmacology**: modern platforms separate an *address* from an *effector*.

- ADC: antibody address + cytotoxic payload.
- Bispecific: two recognition events, often tumor antigen + CD3.
- Radioligand: imaging/ligand address + therapeutic isotope.
- Cell/gene therapy: cell, vector, or sequence address + a durable genetic program.
- RNA medicine: base-pairing address + RISC, RNase H, splice control, or translation.
- Protein degrader: target ligand + E3-ligase recruitment.
- CGP: not a treatment; it identifies the molecular address and follows its evolution.

The highest-confidence growth engines for the next several years are **ADCs, bispecific antibodies, RNA medicines, radioligands, and established cell/gene therapy**. The most important newly validated platform is **heterobifunctional targeted protein degradation**, because its first drug was approved in 2026; molecular-glue degradation has older clinical validation through the IMiD/cereblon story. **Personalized mRNA cancer vaccines** have a meaningful randomized Phase II signal but still need Phase III confirmation. **Microbiome products and oncolytic viruses are real but narrowly successful**, not general-purpose platforms yet. Several mechanism-driven fields that are not new delivery modalities—incretin polyagonists, FcRn blockade, CGRP blockade, anti-amyloid antibodies and long-acting HIV capsid inhibition—also rank among the decade's consequential advances and are covered separately.

Evidence shorthand used below:

- **E1:** randomized benefit on mortality, survival, major clinical events or a well-established hard functional outcome.
- **E2:** randomized benefit on PFS, recurrence or a clinical/functional surrogate, without demonstrated survival benefit.
- **E3:** single-arm registrational evidence and/or accelerated approval.
- **E4:** positive Phase II evidence not yet confirmed as a treatment standard.

These tiers describe an indication's evidence, not an intrinsic property of the platform; one row can contain several tiers.

| Field | Maturity in 2026 | Strongest evidence and important caveat | Best-validated disease territory | Main bottleneck | Most credible next inflection |
|---|---|---|---|---|---|
| ADCs | Established and rapidly expanding | **E1–E3:** OS benefit for T-DXd and enfortumab regimens; several niche targets remain single-arm accelerated approvals | Breast, urothelial, ovarian and lymphoid cancers; selected lung/myeloid subsets | Therapeutic index, heterogeneous antigen, payload cross-resistance | Earlier/curative settings; biomarker- and payload-aware sequencing |
| Bispecific/multispecific antibodies | Established in hematology; solid-tumor proof now real | **E1–E3:** randomized OS for blinatumomab/tarlatamab and randomized Phase III benefit for some lymphoma/myeloma regimens; several rare solid-tumor approvals remain single-arm | ALL, lymphoma, myeloma, SCLC, EGFR-mutant NSCLC, uveal melanoma, hemophilia A | CRS/ICANS, infection, antigen escape, solid-tumor penetration | Earlier and finite-duration use; outpatient/subcutaneous delivery; selected solid tumors |
| Cell therapy | Established for blood cancers; early solid-tumor foothold | **E1** for earlier-line CAR-T in selected blood cancers; **E3** for TIL/TCR approvals; **E4** randomized Phase II plus China-only approval for gastric CAR-T | B-cell malignancies, myeloma; selected melanoma and synovial sarcoma | Bespoke manufacture, conditioning, toxicity, cost, solid-tumor microenvironment | Earlier-line CAR-T, faster/allogeneic supply, broader TCR/TIL use |
| Gene therapy/editing | Regulatory validation across selected monogenic diseases | **E2–E3:** many pivotal programs are small or single-arm because natural history is severe; benefit and risk are highly product-specific | Hemoglobinopathies, retinal/SMA/hearing disorders, hemophilia, leukodystrophies, skin disease | Delivery, conditioning, irreversibility, immune toxicity, durability, economics | First in-vivo CRISPR approval; local/tissue-restricted delivery; non-genotoxic conditioning |
| siRNA/ASO | Repeatable platform; liver delivery largely solved | **E1–E3:** clinical-outcome benefit in ATTR; many other approvals use protein/lipid or disease-specific surrogate endpoints | ATTR amyloidosis, SMA, porphyria, hyperoxaluria, HAE, hemophilia and selected dyslipidemic/genetic disorders | Extrahepatic delivery, endosomal escape, long-exposure toxicity | Common cardiometabolic disease; muscle/CNS delivery; earlier genotype-first treatment |
| Personalized mRNA cancer vaccine | Positive randomized Phase II; not yet a proven cancer standard | **E4:** KEYNOTE-942 was small/open-label and did not meet conventional two-sided significance | Resected high-risk melanoma; several Phase III oncology programs | Neoantigen quality, individualized manufacturing, HLA/antigen escape | A decisive Phase III readout and shorter biopsy-to-dose time |
| Radioligand/theranostic therapy | Established | **E1** VISION OS benefit; **E2** NETTER-1/PSMAfore PFS benefit without significant final OS benefit | SSTR-positive GEP-NET and PSMA-positive prostate cancer | Isotope supply/logistics, heterogeneous target, dosimetry and organ toxicity | Earlier-line use, individualized dosimetry and—if trials succeed—alpha emitters |
| Targeted protein degradation | First heterobifunctional approval in 2026; older molecular-glue precedent | **E2:** vepdegestrant improved PFS only in the ESR1-mutant subgroup; unselected ITT result was negative and OS is immature | ESR1-mutant ER+/HER2− breast cancer; advanced myeloma programs | Drug-like properties, ternary-complex predictability, E3 dependence, resistance | Additional biomarker-selected degraders and more drug-like molecular glues |
| Microbiome ecosystem therapy | Narrowly established | **E2:** randomized reduction in recurrent CDI; no platform-level validation outside this setting | Prevention of recurrent *C. difficile* after antibiotics | Donor/lot variability, pathogens, engraftment and mechanism | Defined, cultured consortia—probably first in recurrent CDI |
| Oncolytic/viral immunotherapy | Technically validated, limited systemic impact | **E2–E3:** local response/surgery-avoidance evidence; no demonstrated systemic OS platform | Injectable melanoma lesions; recurrent respiratory papillomatosis | Local delivery, antiviral immunity, variable replication, manufacturing | Success in repeatedly accessible organs/lesions; systemic benefit remains unproven |
| CGP | Enabling diagnostic, not a modality | Not applicable: requires analytical validity plus prospective evidence that acting on a result improves outcomes | Precision oncology across many tumor types | Actionability, heterogeneity, low tumor fraction, CHIP/VUS, access | Longitudinal cfDNA, RNA/fusion layers and prospectively validated MRD-guided treatment |

## 1. Antibody–drug conjugates (ADCs)

### History and proof

The first ADC, gemtuzumab ozogamicin, was approved in 2000, withdrawn after toxicity and an unfavorable confirmatory result, and successfully reintroduced in 2017 using a lower fractionated schedule. That history established a central principle: **antibody, linker, payload, drug-to-antibody ratio, dose and schedule form one indivisible pharmacologic system**.

Brentuximab vedotin and trastuzumab emtansine established the modern platform in 2011–2013. The major 2019–2026 inflection came from cleavable linkers, membrane-permeable payloads, higher drug loading and bystander killing. Trastuzumab deruxtecan (T-DXd) is the clearest example: in DESTINY-Breast04, it improved both progression-free and overall survival in HER2-low metastatic breast cancer, while drug-related ILD/pneumonitis occurred in 12.1% and was fatal in 0.8% ([primary Phase III report](https://www.nejm.org/doi/full/10.1056/NEJMoa2203690)). This was biologically important because an ADC converted low antigen expression—previously considered “HER2 negative”—into an actionable phenotype.

The platform now covers HER2-positive/low/ultralow breast cancer; HER2 gastric and lung cancers; Nectin-4-positive urothelial cancer; Trop-2-positive breast and lung cancers; FRα-high ovarian cancer; and CD30, CD79b, CD33 and other hematologic targets. Enfortumab vedotin plus pembrolizumab nearly doubled median overall survival versus platinum chemotherapy in first-line advanced urothelial cancer, showing that ADCs can become treatment backbones rather than late-line salvage ([EV-302](https://www.nejm.org/doi/full/10.1056/NEJMoa2312117)). Evidence for newer niches is weaker: the 2025 breast-cancer approval of datopotamab rested on randomized PFS benefit without significant OS improvement, while c-Met-high NSCLC approval of telisotuzumab vedotin was accelerated from a single-arm response study ([FDA datopotamab](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast), [FDA telisotuzumab](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression)).

### Main problems

- Tumor antigen expression is spatially and temporally heterogeneous; one archival biopsy is often a poor model of metastatic disease.
- Resistance can arise through antigen loss, defective internalization/lysosomal processing, efflux, altered tubulin/topoisomerase biology or DNA-repair adaptation.
- “Targeted delivery” does not abolish systemic toxicity. Important liabilities include ILD, marrow suppression, neuropathy, ocular injury, rash, hyperglycemia and hepatic sinusoidal obstruction, depending on the product.
- Many new ADCs reuse topoisomerase-I payloads. Cross-resistance and optimal sequencing after a prior ADC are major unanswered questions.
- Accelerated approvals based on response can fail confirmation. Sacituzumab's urothelial indication was withdrawn in 2024 after the confirmatory trial failed to improve survival ([FDA withdrawn indications](https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals)). Belantamab's original single-agent myeloma indication was withdrawn after a failed confirmatory trial, then FDA approved a different bortezomib/dexamethasone combination on 23 October 2025 after randomized DREAMM-7 benefit; ocular toxicity occurred in 92% and was grade 3–4 in 77% ([FDA 2025 approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma)). This is a useful warning against class-level optimism and against confusing a product's return in a new regimen with confirmation of its original use.

### Most likely next breakthroughs

The highest-confidence advances are earlier, potentially curative use; first-line ADC–immunotherapy combinations; quantitative/spatial antigen measurement instead of binary IHC; and resistance-aware sequencing in which target, linker and payload are treated as separate biomarkers. The main scientific prize is **a wider therapeutic index**, not simply another surface target.

## 2. Bispecific and multispecific antibodies

### History and proof

Blinatumomab (CD19×CD3) in 2014 began the modern US era. Emicizumab (FIXa×FX) in 2017 proved that a bispecific can also reproduce a missing physiologic cofactor rather than redirect cytotoxicity. The field now contains four clinically validated architectures: CD3 T-cell engagers, peptide-HLA×CD3 soluble TCR fusions, dual-receptor/biparatopic antibodies and dual-pathway antibodies.

The strongest hematology validation includes blinatumomab in ALL; CD20×CD3 agents in lymphoma; and BCMA×CD3 or GPRC5D×CD3 agents in myeloma. In March 2026, teclistamab plus daratumumab moved into patients after only one prior line and converted teclistamab monotherapy to traditional approval, an important transition from late-line single-arm evidence to randomized Phase III benefit ([FDA](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-combination-daratumumab-hyaluronidase-fihj-relapsed-or-refractory-multiple)).

Solid tumors are harder, but no longer a theoretical aspiration. Tebentafusp, a gp100/HLA-A*02:01×CD3 soluble TCR, improved survival in metastatic uveal melanoma despite a low conventional response rate. Tarlatamab (DLL3×CD3) gained traditional approval in 2025 after improving survival over chemotherapy in previously treated extensive-stage SCLC ([FDA](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer)). Amivantamab (EGFR×MET) is established in molecular subsets of NSCLC. Zanidatamab (biparatopic HER2) and zenocutuzumab (HER2×HER3) have approvals in selected HER2- or NRG1-driven cancers, but these are small, single-arm accelerated-approval datasets rather than randomized survival proof.

A second solid-tumor direction is dual checkpoint/angiogenesis biology. Ivonescimab (PD-1×VEGF) improved PFS versus pembrolizumab in the China-only randomized HARMONi-2 trial and is approved in China for selected NSCLC settings ([primary report](https://pubmed.ncbi.nlm.nih.gov/40057343/)). It is a major watch item, but not a global standard: geographic generalizability, OS, bleeding/thrombotic toxicity and the value of physical colocalization versus simply combining two drugs still require confirmation.

### Diseases with meaningful proof

- B-ALL, follicular and large B-cell lymphoma, and multiple myeloma.
- SCLC, EGFR-mutant NSCLC, metastatic uveal melanoma and selected biliary/pancreatic molecular subsets.
- Hemophilia A, wet AMD, diabetic macular edema and retinal-vein-occlusion edema for non-CD3 formats.

### Main problems

CRS and ICANS dominate early management, while chronic infection, hypogammaglobulinemia and cytopenias can dominate long-term harm. Antigen loss, lineage switch, target-density thresholds and T-cell exhaustion limit duration. GPRC5D targeting illustrates target-specific on-target/off-tumor toxicity through dysgeusia, skin/nail effects and weight loss. Solid tumors add poor penetration, stroma, immune suppression and on-target/off-tumor risk. Geometry, affinity, valency and Fc behavior strongly affect efficacy and safety: two molecules with the same named targets are not necessarily equivalent drugs.

### Most likely next breakthroughs

Earlier-line and fixed-duration hematologic regimens, response-adapted stopping, subcutaneous/outpatient delivery and expansion from validated solid-tumor anchors such as DLL3 are more credible than simply adding a third binding arm. Better longitudinal biomarkers of target density, T-cell fitness and ctDNA response are likely to matter more than molecular complexity alone.

## 3. Cell therapy within CGT

### CAR-T

CD19 CAR-T gained its first US approval in 2017; BCMA CAR-T followed in myeloma. Randomized Phase III trials have moved CAR-T earlier than salvage transplant in large B-cell lymphoma and after only one to three prior lines in lenalidomide-refractory myeloma ([ZUMA-7](https://www.nejm.org/doi/10.1056/NEJMoa2116133), [CARTITUDE-4](https://www.nejm.org/doi/full/10.1056/NEJMoa2303379)). Established diseases now include B-ALL, several B-cell lymphomas, CLL/SLL and multiple myeloma.

Solid-tumor validation began in adjacent adoptive-cell platforms and, in June 2026, CLDN18.2-directed satri-cel became the first approved solid-tumor CAR-T, in China, for selected gastric/GEJ cancer. Its randomized Phase II PFS benefit was real but the absolute median PFS remained short; this is an important foothold, not evidence that solid-tumor CAR-T is broadly established ([Phase II report](https://pubmed.ncbi.nlm.nih.gov/40460847/), [China approval report](https://english.pudong.gov.cn/2026-06/24/c_1192878.htm)).

The central problems are bespoke manufacturing, vein-to-vein delay, product failure, lymphodepletion, CRS, ICANS, prolonged cytopenia, infection, antigen escape and cost. FDA removed the original CAR-T REMS programs in 2025 as clinical management matured, but class labeling still warns about rare secondary T-cell malignancies and requires lifelong awareness; this signal should not be confused with the more frequent acute toxicities, infections and cytopenias, and causality must be assessed product by product ([FDA safety communication](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed)). Solid tumors additionally require trafficking, persistence and survival within heterogeneous, fibrotic and immunosuppressive tissue.

High-confidence progress is earlier-line hematologic use. Medium-confidence opportunities are allogeneic/off-the-shelf supply, dual-antigen designs, selected autoimmune “immune reset” indications and additional solid-tumor niches. In-vivo CAR generation is intentionally excluded here because it has not yet cleared the evidence threshold.

### TIL and engineered TCR therapy

Lifileucel became the first FDA-approved TIL therapy in 2024 for PD-1-refractory metastatic melanoma, based on a Phase II response rate around 31% with durable benefit in a minority ([FDA](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma)). Afamitresgene autoleucel became the first approved engineered TCR therapy the same year for HLA-restricted, MAGE-A4-positive synovial sarcoma ([FDA](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecelra)).

TCRs matter because they can recognize intracellular lineage or oncogenic antigens presented by HLA, far beyond the surface-antigen space accessible to CARs. The costs are HLA restriction, dependence on antigen processing, potential catastrophic cross-reactivity and tumor escape through loss of antigen or HLA. TIL therapy requires tumor resection, weeks of expansion, intense lymphodepletion and often high-dose IL-2. The next credible disease areas are melanoma, sarcoma, HPV-associated cancers, NSCLC and selected antigen-positive epithelial tumors.

## 4. Gene therapy and genome editing within CGT

### Ex-vivo HSC engineering

Gene-therapy history began with the 1990 ADA-SCID ex-vivo trial in peripheral-blood T cells; HSC engineering followed. Safer lentiviral vectors ultimately produced approved HSC products for β-thalassemia, sickle-cell disease, cerebral adrenoleukodystrophy, metachromatic leukodystrophy and, in December 2025, Wiskott–Aldrich syndrome ([FDA Waskyra approval](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome)). Casgevy, approved in 2023–2024, provided the first commercial proof of CRISPR editing: autologous HSCs are edited at the erythroid BCL11A enhancer to reactivate fetal hemoglobin. Its single-arm registrational trial found 29 of 30 evaluable severe-SCD patients free of vaso-occlusive crises for at least 12 consecutive months; the treated and evaluable denominators should not be conflated. FDA expanded use to children aged two and older in July 2026 ([primary trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2309676), [FDA 2026 expansion](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease)).

The largest remaining burden is not the edit itself but the procedure: mobilization/apheresis, individualized manufacture, busulfan myeloablation, infertility, infection, mucositis, hepatic toxicity and prolonged hospitalization. This is especially problematic because SCD and thalassemia are commonest where transplant infrastructure is least available. Lentiviral products retain product-specific insertional/clonal risk: Lyfgenia carries a hematologic-malignancy boxed warning, and FDA has reported substantial malignancy risk with Skysona; these findings should not be generalized numerically to every vector/product ([Lyfgenia label](https://www.fda.gov/media/174610/download), [FDA Skysona safety update](https://www.fda.gov/vaccines-blood-biologics/fda-approves-required-labeling-changes-increased-risk-hematologic-malignancy-following-treatment)). Nuclease editing substitutes uncertainties around off-target edits, large on-target rearrangements and very-long-latency clonal risk.

The decisive breakthrough would be non-genotoxic antibody/ADC conditioning or direct in-vivo HSC editing, eliminating busulfan and perhaps apheresis.

### In-vivo gene addition

AAV or locally delivered viral products now treat selected RPE65 retinal dystrophy, SMA, hemophilia A/B, dystrophic epidermolysis bullosa, AADC deficiency, DMD and OTOF-associated hearing loss. The 2026 accelerated approval of dual-AAV Otarmeni shows that even the AAV payload limit can sometimes be engineered around, but its evidence was a small single-arm cohort—16 of 20 efficacy-evaluable patients improved—and durability/functional confirmation is still required ([FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher)).

The platform’s problems remain formidable: pre-existing and induced capsid immunity, poor redosing, hepatic/complement/TMA toxicity, steroid exposure, declining expression, tissue tropism, full/empty-capsid potency control, a roughly 4.7-kb payload limit and exceptional manufacturing cost. Elevidys is the decade's sharpest evidence-and-safety case: its large randomized study missed the prespecified NSAA primary endpoint, FDA nevertheless granted broader approval in 2024 based on the totality of secondary/exploratory evidence, and fatal liver injury later caused FDA to restrict the 2025 label to ambulatory DMD patients aged four and older and add a boxed warning ([FDA 2024 evidence discussion](https://www.fda.gov/news-events/press-announcements/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy), [FDA 2025 restriction](https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal)). Platform success never substitutes for product-level evidence and safety. Commercial withdrawals of approved hemophilia products also show that adoption can fail because chronic competitors, uncertain durability and reimbursement make the value proposition weak.

The credible future is engineered capsids, tissue-restricted promoters, local administration, redosable HSV platforms and treatment before tissue loss—not a blanket expectation that systemic high-dose AAV will solve common disease.

### In-vivo genome editing

Liver-targeted LNP delivery has produced the clearest proof. Lonvoguran ziclumeran (formerly NTLA-2002) knocks out *KLKB1* after one infusion. The randomized Phase II HAE study reduced attacks by about 75% versus placebo ([Phase II](https://www.nejm.org/doi/10.1056/NEJMoa2405734)). In the 80-patient randomized Phase III HAELO trial published in June 2026, attack rate fell 87% versus placebo and 62% of treated patients were attack- and prophylaxis-free versus 11% on placebo, at still-short median follow-up of 7.5 months ([Phase III](https://www.nejm.org/doi/10.1056/NEJMoa2600931)). This makes a first in-vivo CRISPR approval plausible, but does not yet establish lifelong durability. The major constraints are irreversibility, off-target and large on-target changes, uncertain cancer latency, anti-Cas immunity, infusion/hepatic injury and the current practical confinement of efficient systemic editing to hepatocytes.

Base editing, prime editing and in-vivo knock-in are not foregrounded because most programs remain below the requested maturity threshold.

## 5. RNA medicines: siRNA, ASO and mRNA

### siRNA and ASO

Nusinersen’s 2016 approval established splice-modifying ASO therapy in SMA; patisiran became the first approved siRNA in 2018. Chemical stabilization, lipid nanoparticles and especially hepatocyte-targeted GalNAc conjugation transformed RNA interference into a repeatable platform. Patisiran improved neuropathy and quality of life in hereditary ATTR amyloidosis ([APOLLO](https://www.nejm.org/doi/full/10.1056/NEJMoa1716153)). Vutrisiran then moved RNAi into a larger cardiology population: in HELIOS-B it reduced death/recurrent cardiovascular events in ATTR cardiomyopathy and preserved function and quality of life ([Phase III report](https://www.nejm.org/doi/full/10.1056/NEJMoa2409134)).

Approved disease areas now include ATTR polyneuropathy/cardiomyopathy, SMA, acute hepatic porphyria, primary hyperoxaluria, hypercholesterolemia, familial chylomicronemia, hereditary angioedema, hemophilia A/B and selected genotype-defined neurologic disorders. Evidence strength varies. Inclisiran is approved on LDL-C lowering while cardiovascular-outcome confirmation remains pending; tofersen for SOD1-ALS was accelerated-approved on neurofilament lowering, not yet proven clinical benefit ([ORION-4 registry](https://clinicaltrials.gov/study/NCT03705234), [FDA tofersen explanation](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene)).

Delivery is the governing constraint. Liver delivery is excellent; efficient delivery to muscle, lung, immune cells, solid tumors and diffuse CNS remains difficult. CNS ASOs often require repeated lumbar puncture, and endosomal escape is inefficient. Risks are molecule-specific but include thrombocytopenia, hepatic/renal injury, complement or innate immune activation, injection reactions and exaggerated pharmacology. Long exposure is convenient until toxicity appears and cannot be rapidly reversed.

The most likely breakthroughs are movement into common cardiometabolic disease, extrahepatic conjugates, earlier genotype-first intervention and less frequent dosing. The correct efficacy question is not “how much protein was knocked down?” but “did a clinically meaningful outcome improve?”

### Personalized mRNA cancer vaccines

COVID-19 and RSV vaccines validated mRNA/LNP manufacturing, but therapeutic oncology remains a separate evidentiary question. In the randomized Phase IIb KEYNOTE-942 study of 157 patients with resected high-risk melanoma, individualized V940 plus pembrolizumab produced an encouraging recurrence-free-survival signal, but the confidence interval crossed 1 under conventional testing and no mature OS evidence exists ([primary report](https://pubmed.ncbi.nlm.nih.gov/38246194/)). A blinded Phase III melanoma trial is underway.

The bottlenecks are tumor sequencing and HLA typing, imperfect neoantigen prediction, individualized GMP manufacture and release, turnaround time, and escape through antigen/HLA loss or immune exclusion. If Phase III is positive, the breakthrough will be not only efficacy but a scalable manufacturing system that converts each tumor into a reproducible drug within weeks.

## 6. Radioligand and radiopharmaceutical theranostics

Radioiodine is old; the modern innovation is paired diagnostic and therapeutic targeting—“see what you treat, treat what you see.” NETTER-1 established lutetium-177 dotatate in SSTR-positive **midgut** neuroendocrine tumors, leading to the broader labeled GEP-NET indication for Lutathera in 2018; its final OS comparison was not statistically significant despite the large PFS effect ([NETTER-1](https://www.nejm.org/doi/full/10.1056/NEJMoa1607427)). VISION established lutetium-177 PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer, with improvement in both radiographic PFS and OS ([VISION](https://www.nejm.org/doi/full/10.1056/NEJMoa2107322)). FDA moved Pluvicto before taxane chemotherapy in appropriate patients in 2025 on PSMAfore's rPFS benefit; OS was not statistically significant and was difficult to interpret because of extensive crossover ([FDA](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication)).

Established diseases are SSTR-positive gastroenteropancreatic neuroendocrine tumors and PSMA-positive mCRPC. The main problems are heterogeneous/lost target expression, marrow and renal toxicity, salivary/lacrimal uptake and xerostomia, cumulative radiation, infertility, small long-term MDS/leukemia risk, isotope production and transport, short shelf life, specialized-center capacity and waste handling. Fixed administered activity also ignores large interpatient differences in absorbed tumor and organ dose.

The most credible advances are earlier-line use, patient-specific dosimetry and rational combinations. Alpha emitters may improve killing over a short path length, but they remain a watch item until randomized trials validate the class; isotope supply, especially actinium-225, is itself a development bottleneck.

## 7. Targeted protein degradation

The PROTAC concept was introduced in 2001, and the first rational heterobifunctional degrader entered human testing in 2019. On 1 May 2026, FDA approved vepdegestrant, the first heterobifunctional protein degrader, for ESR1-mutated ER-positive/HER2-negative advanced breast cancer after endocrine therapy ([FDA](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast)). In the biomarker-selected group, median PFS was 5.0 versus 2.1 months with fulvestrant (HR 0.57); the unselected intention-to-treat population was not significant. This is convincing proof that the modality can work, not proof of universal superiority over inhibitors.

The major problems are large, flexible, poorly soluble molecules; oral exposure and tissue penetration; difficult-to-predict ternary-complex geometry; overreliance on CRBN and VHL; resistance through target/E3/ubiquitin-system changes; unintended neosubstrate degradation; and normal-tissue loss of the intended target. A catalytic mechanism does not remove dose, distribution or toxicity constraints.

The likely next breakthroughs are additional biomarker-selected degraders; more drug-like molecular glues; tissue-restricted E3 ligases; structural prediction of productive ternary complexes; and degradation of transcription factors or scaffolds that lack a conventional active site.

## 8. Narrow but real platforms

### Microbiome ecosystem therapy

Rebyota (2022) and oral Vowst (2023) validated restoration of colonization resistance after recurrent *C. difficile*. In Vowst’s randomized trial, eight-week recurrence was 12.4% versus 39.8% with placebo ([FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-first-orally-administered-fecal-microbiota-product-prevention-recurrence-clostridioides)). This does **not** validate microbiome therapy for IBD, obesity, cancer response, neuropsychiatric disease or vague “gut health.” Donor-derived products carry pathogen risk, lot variation, uncertain active components and variable engraftment. The most plausible next step is a defined, cultured consortium, initially in recurrent CDI.

### Oncolytic and viral immunotherapy

T-VEC was approved in 2015 for injectable unresectable melanoma lesions, but its label does not claim improved OS or control of visceral disease, and adding it to pembrolizumab failed to improve PFS or OS in Phase III. In 2025, Papzimeos, a non-replicating adenoviral HPV6/11 immunotherapy, was approved for recurrent respiratory papillomatosis, with 18 of 35 pivotal-trial patients avoiding surgery for 12 months ([FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-first-immunotherapy-recurrent-respiratory-papillomatosis)). An adjacent local viral-gene-therapy success is intravesical nadofaragene firadenovec (Adstiladrin), approved in 2022 for BCG-unresponsive non-muscle-invasive bladder cancer; it supports the idea that repeatedly accessible organs are more tractable than systemic delivery ([FDA](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/adstiladrin)). Systemic oncolytic efficacy remains unvalidated.

## 9. CGP: comprehensive genomic profiling (working interpretation)

In this context, **CGP most likely means comprehensive genomic profiling**. CGRP migraine biology is covered separately below in case “CGP” was a shorthand or typo.

CGP is a diagnostic and drug-development infrastructure, not a drug modality. FoundationOne CDx became an FDA-approved broad NGS companion diagnostic in 2017, interrogating 324 genes plus signatures such as MSI and TMB ([FDA PMA](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019)). Plasma cfDNA profiling gained companion-diagnostic uses in 2020, with the important warning that a negative plasma test does not prove a tumor is negative ([FDA liquid-biopsy approval](https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test)). In 2024, TruSight Oncology Comprehensive added DNA analysis across 517 genes and RNA fusion/splice analysis across 25 ([FDA](https://www.fda.gov/medical-devices/recently-approved-devices/trusight-oncology-comprehensive-p230011)).

CGP enabled basket trials and tissue-agnostic therapy: MSI/dMMR immune checkpoint treatment, NTRK and RET fusion inhibitors, and rapid genotype-defined development in lung, breast, colorectal, prostate, ovarian, thyroid and biliary cancers. It is also inseparable from the recent success of “formerly undruggable” targets such as KRAS G12C.

Its central problem is no longer sequencing capacity but **clinical actionability**. Low ctDNA shedding causes false negatives; clonal hematopoiesis can cause false positives; tumor heterogeneity and evolution defeat static testing; many variants are uncertain; incidental germline findings require management; and a molecular match may not provide access to an effective drug or trial. The next 3–7 years should bring longitudinal cfDNA, RNA/fusion and methylation layers and better resistance monitoring. Molecular residual disease is highly prognostic, but changing therapy on MRD still needs prospective interventional proof.

## 10. Checkpoint blockade: mature, but still the combination backbone

PD-1 inhibitors were first approved in 2014, just outside a strict ten-year window, but their largest disease expansion occurred during it. The 2015 Phase II observation that mismatch-repair-deficient tumors are selectively sensitive to PD-1 blockade led to the first tissue-agnostic cancer approval in 2017 ([primary study](https://www.nejm.org/doi/full/10.1056/NEJMoa1500596), [FDA review](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125514Orig1s014.pdf)). Checkpoint blockade now functions as the combination backbone for ADCs, vaccines, chemotherapy and some targeted therapies.

The unresolved problems are primary/acquired resistance, poor biomarkers, immune-related toxicity and a long history of failed empiric combinations. LAG-3 plus PD-1 (relatlimab/nivolumab) shows that an additional checkpoint can work, but the broader lesson from many failures is that new checkpoints and combinations need biomarker selection, mechanistic justification and randomized evidence rather than analogy alone ([RELATIVITY-047](https://www.nejm.org/doi/full/10.1056/NEJMoa2109970)). Earlier/perioperative treatment is already becoming a major use case.

## 11. Major mechanism-driven fields beyond the core modality list

These are not fundamentally new delivery formats, but omitting them would distort which drug-development ideas actually changed medicine during the decade.

### Engineered incretin and multi-agonist peptides

Long-acting GLP-1 biology moved from glucose lowering into obesity and hard cardiovascular outcomes; tirzepatide then validated dual GIP/GLP-1 agonism. Semaglutide reduced major adverse cardiovascular events from 8.0% to 6.5% in 17,604 people with overweight/obesity and established cardiovascular disease but no diabetes (HR 0.80), making this **E1** evidence rather than a weight-loss surrogate ([SELECT](https://www.nejm.org/doi/full/10.1056/NEJMoa2307563)). Tirzepatide has randomized Phase III obesity benefit and, in 2024, became the first FDA-approved drug for moderate-to-severe obstructive sleep apnea in adults with obesity ([FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea)).

Validated diseases now include type 2 diabetes, obesity, cardiovascular-risk reduction in a defined obesity population and obesity-associated OSA. The current problems are gastrointestinal intolerance, gallbladder disease, loss of lean mass along with fat, treatment discontinuation and weight regain, chronic cost/access and uncertain long-term sequencing. The next wave is oral delivery, longer intervals and triple/multi-agonists, but each needs outcome evidence rather than greater percentage weight loss alone.

### FcRn blockade for pathogenic-IgG disease

Efgartigimod became the first FcRn antagonist in 2021, initially for AChR-antibody-positive generalized myasthenia gravis; later approvals and competitors expanded the class ([FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis)). The platform accelerates catabolism of IgG without broad cytotoxic immune depletion. Strongest proof is in generalized myasthenia gravis and CIDP, with Phase II/III programs across other autoantibody-mediated diseases.

The main problems are transient rather than curative control, repeated dosing, infection risk from lowering total IgG, variable response across autoantibody biology and uncertain optimal sequencing against B-cell/plasma-cell therapies. The next breakthrough would be disease- and antibody-specific biomarkers that distinguish patients needing rapid IgG removal from those needing durable elimination of antibody-producing clones.

### CGRP pathway blockade in migraine

If “CGP” meant **CGRP**, this is the relevant field. Erenumab, the first CGRP-receptor antibody, was approved in 2018; ligand antibodies and oral/intranasal gepants followed for preventive and acute treatment ([FDA erenumab label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf)). It is a clean translational success from human migraine biology to target-specific medicines, with established benefit in episodic and chronic migraine and selected cluster-headache use.

Problems are incomplete/nonresponse, cost, injection burden for antibodies, constipation and hypertension signals with receptor blockade, drug interactions and molecule-specific hepatic considerations for gepants, and limited evidence that treatment modifies the underlying disease. The likely progress is better response prediction and flexible acute-plus-preventive regimens rather than a wholly new mechanism.

### Long-acting HIV capsid inhibition

Lenacapavir validated a new viral target in multidrug-resistant HIV and then transformed prevention through six-monthly dosing. In PURPOSE 2, HIV incidence was 0.10 versus 0.93 per 100 person-years with daily oral F/TDF; PURPOSE 1 observed no incident infections among more than 2,000 women receiving lenacapavir during the primary analysis ([PURPOSE 2](https://www.nejm.org/doi/10.1056/NEJMoa2411858)). FDA approved twice-yearly Yeztugo for PrEP in June 2025 ([FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220018s000lbl.pdf)).

The principal problems are resistance if infection is missed or companion drugs fail, the long pharmacokinetic “tail” after discontinuation, injection-site nodules/reactions, drug interactions and the implementation challenge of delivering on-time injections at population scale. The next breakthrough is as much a public-health delivery system as a molecule.

### Anti-amyloid antibodies in early Alzheimer disease

Lecanemab received traditional FDA approval in 2023 and donanemab in 2024 after randomized Phase III trials showed statistically significant but modest slowing of cognitive/functional decline ([lecanemab trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2212948), [FDA lecanemab decision](https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval)). These are genuine target-validation successes but also a stress test for what “clinically meaningful” means.

Use is limited to biomarker-confirmed early disease. Problems include amyloid-related imaging abnormalities (especially in APOE ε4 homozygotes), infusion and serial-MRI burden, rare serious/fatal hemorrhage, uncertain individual perceptibility of the average benefit and substantial system cost. Future progress depends on easier blood biomarkers, safer/subcutaneous administration and trials before substantial neuronal loss—not simply greater plaque removal.

## Cross-platform problems to watch

1. **Therapeutic index:** on-target/off-tumor injury is the shared limit for ADCs, bispecifics, CAR/TCR cells and radioligands.
2. **Heterogeneity and evolution:** antigen, HLA and target loss make longitudinal profiling and rational sequencing essential.
3. **Delivery:** liver is tractable for RNA and in-vivo editing; diffuse CNS, muscle and solid tumors remain difficult.
4. **Manufacturing and access:** autologous cells, HSC editing, isotopes and individualized vaccines are logistics systems as much as drugs.
5. **Durability and reversibility:** permanent editing and long-lived exposure are valuable only if long-term safety is predictable.
6. **Evidence quality:** accelerated approval, ORR and biomarker knockdown are hypotheses about clinical benefit, not substitutes for randomized PFS, OS, function or quality of life.
7. **Economics:** one-time therapies may be biologically transformative but commercially fragile when chronic alternatives are safe, effective and easier to reimburse.

## My probability-weighted 2026–2033 watch list

### High confidence

- ADC and bispecific movement into earlier-line treatment.
- More outcome-validated liver-directed RNA medicines in common cardiometabolic disease.
- Earlier radioligand use and better individualized dosimetry.
- More ex-vivo HSC and local/tissue-confined gene-therapy approvals.
- A first in-vivo CRISPR approval, most plausibly from a liver-directed knockout program.

### High impact, medium confidence

- A positive Phase III personalized mRNA cancer-vaccine result.
- Additional approved protein degraders beyond ER, especially in biomarker-selected cancer.
- CAR-T/TCR/TIL expansion into selected solid tumors and autoimmune disease.
- Non-genotoxic conditioning that materially reduces the procedural burden of HSC therapy.
- Alpha radiopharmaceuticals with randomized benefit and viable isotope supply.

### Narrow or low confidence until better evidence arrives

- Broad microbiome efficacy outside recurrent CDI.
- Systemic oncolytic-virus benefit.
- Off-the-shelf CAR-T matching autologous durability across diseases.
- Redosable systemic AAV at scale.
- AI-designed drugs as a distinct therapeutic modality; AI is a discovery tool and Phase II entry alone does not prove a higher clinical success rate.

## A practical system for staying current

Use a monthly rather than daily cadence. Track four evidence streams:

1. **Regulatory:** [FDA oncology approvals](https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications), [FDA approved cellular/gene therapies](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products), EMA EPARs and FDA safety communications.
2. **Trials:** ClinicalTrials.gov saved searches restricted to Phase II/III and the named modalities. Trial entry is a signal; randomized readout is evidence.
3. **Primary literature:** PubMed alerts for `(ADC OR bispecific OR CAR-T OR TCR OR TIL OR gene editing OR siRNA OR antisense OR radioligand OR PROTAC) AND (phase 2 OR phase 3)`.
4. **Meetings:** late-breaking sessions from AACR, ASCO, ESMO, ASH, ASGCT, SITC and SNMMI. Treat company press releases as readout alerts, then verify the protocol, denominator, follow-up and primary publication.

For each event, record: **target/address; effector/payload; population and biomarker; trial phase/design; comparator; primary endpoint; absolute benefit; duration; grade 3–5 and treatment-related deaths; manufacturing/logistics; regulatory status; next confirmatory event**. This format makes failures and withdrawals as informative as approvals.

## Explicit exclusions

Exosomes/extracellular-vesicle therapies, LYTAC/AUTAC/AbTAC systems, most base/prime-editing programs, epigenetic partial reprogramming, mRNA protein replacement and in-vivo CAR engineering are excluded from the core landscape because human efficacy is below the requested maturity level or too immature to call successful. Phage therapy and broad microbiome claims are also excluded for lack of consistent platform-level clinical validation. Alpha radiopharmaceuticals and personalized mRNA cancer vaccines are retained only as Phase II/III watch items, not described as approved therapeutic classes.